

CME Symposium

IN ASSOCIATION WITH THE 7th



EARN
CME
ABIM-MOC
CREDITS
1.75

Heart and Kidney: Hitting Two Birds with One Stone



Friday, June 9, 2023
7:15 pm – 9:00 pm EST
Hilton Penn's Landing
Philadelphia, PA
DINNER WILL BE SERVED

All content available ON-DEMAND for ONE YEAR following the meeting.

This is a CME Symposium Supported by an Educational Grant from **AstraZeneca**

Free for all 7th HiD Attendees. Register online www.heartindiabetes.com/registration

Jointly Provided By: **MEEF**
FOUNDATION

PESI

ABIM
CME MOC
ACCREDITED

Administered By: **TMIOA**



HF AND CKD: HITTING TWO BIRDS WITH ONE STONE

CHAIRS: **Yehuda Handelsman, MD • Mikhail Kosiborod, MD**

7:15 pm	Introduction & Pre-CME Questions Mikhail N. Kosiborod, MD
7:25 pm	The Intersection of CKD and HF- Making the Link Matthew R. Weir, MD
7:45 pm	Contemporary Approach to Management of CKD Katherine R. Tuttle, MD
8:05 pm	Management of HF Across the LVEF Spectrum John McMurray, MD
8:25 pm	Panel Discussion and Q&A: Do Guidelines-Directed Medical Therapy Address the Complex Patient with both HF & CKD. Panel: Mikhail N. Kosiborod, MD • John McMurray, MD Katherine R. Tuttle, MD • Matthew R. Weir, MD Moderator: Yehuda Handelsman, MD
8:55 pm	Concluding Remarks & Post-CME Questions
9:00 pm	Adjourn

Program Description

Chronic kidney disease (CKD) and Heart failure (HF) share common etiologies, including hypertension, Diabetes, inflammation, oxidative stress, and increased RAS activity. In recent years, multiple cardiovascular outcome trials (CVOTs) have shown that adverse outcomes in patients with HF and CKD may be reduced with use of a sodium glucose cotransporter 2 (SGLT2) inhibitor. Currently the SGLT2 inhibitor dapagliflozine is indicated to manage CKD and SGLT2i are now recommended as a foundational therapy across the spectrum of left ventricular ejection fraction (LVEF).

This satellite symposium will explore the changing landscape of therapies for patients with HF and/or CKD, with or without diabetes. The program will be held in conjunction with the 7th Annual HID and will address gaps in physicians' knowledge of the interconnections between CKD and heart failure and how to comprehensively manage these conditions when they are present in the same patient.

Learning Objectives

Upon completion of this CME symposium, participants should be able to:

- Describe the epidemiology and common pathophysiologic pathways of HF and CKD
- Discuss outcome trial evidence underlying recently approved therapies for CKD in patients with and without diabetes
- Explain how HF with different degrees of LVEF should be diagnosed and managed based on current guidelines and outcome trial evidence
- Develop treatment strategies for patients with complicated disease, including those with HF and CKD, both with and without diabetes

Target Audience

This educational initiative is designed for cardiologists, nephrologists, endocrinologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of CKD and HF in cardiometabolic Diseases with and without Diabetes.

FACULTY



Mikhail N. Kosiborod MD *Chair*
FACC, FAHA

Professor of Medicine
Saint Luke's Mid America Heart Institute
University of Missouri-Kansas City
School of Medicine
Chair, Heart in Diabetes
Kansas City, Missouri



Yehuda Handelsman, MD *Chair*
FACC, FAHA, FACP, FNLA, FASPC, FAHA, MACE

Medical Director & Principal Investigator
The Metabolic Institute of America
Chair Scientific Advisory board, DCMi— Diabetes
CardioRenal & Metabolism Institute
Chair & Program Director, Heart in Diabetes
Tarzana, California



Matthew R. Weir, MD

Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland



**John McMurray, MD, BSC (Hons),
MB ChB (Hons), FRCP, FESC, FACC, FAHA
FRSE, FMedSci, OBE**

Professor of Medical Cardiology and Deputy Director
Institute of Cardiovascular and Medical Sciences
Honorary Consultant Cardiologist
Queen Elizabeth University Hospital
Glasgow, Scotland



Katherine R. Tuttle MD
FASN, FACP, FNKF

Professor of Medicine, Division of Nephrology
Co-Principal Investigator
Institute of Translational Health Sciences
Executive Director for Research, Providence Health Care
Spokane, Washington

CME DINNER SYMPOSIUM

This CME Supported Symposium is **FREE** for 7th HiD attendees and will stay on demand for **ONE** year following the meeting

Learn more at www.heartindiabetes.com/cmесymposium

To register to the entire Heart in Diabetes meeting
please visit www.heartindiabetes/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Administrated by the Metabolic Institute of America

PESI, Inc. designated this live educational activity
for a maximum of 1.75 AMA PRA Category 1 Credit(s).

Physicians should only claim credit commensurate with the extent
of their participation in the activity.

For more information, please contact: info@tmioa.com or **818.342.1889**

This is a CME program Supported by an Educational Grant from **AstraZeneca**